Kamlyn Jones, MD
Family Medicine · New Bern, NCNPI 1104860717
Payments from drug & device makers
Across 224 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$441
- Amgen$438
- Lilly USA, LLC$429
- GSK$305
- AbbVie$243
- Abbott$163
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,321100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $441 |
| Amgen | 30 | $438 |
| Lilly USA, LLC | 27 | $429 |
| GSK | 19 | $305 |
| AbbVie | 16 | $243 |
| Abbott | 11 | $163 |
| Amarin Pharma, Inc. | 14 | $160 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $150 |
| Boehringer Ingelheim | 9 | $145 |
| Astellas Pharma US Inc | 8 | $123 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $94 |
| AstraZeneca(2 entities) | 4 | $59 |
| Daiichi Sankyo Inc. | 4 | $57 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Pfizer | 3 | $42 |
| Novartis | 3 | $39 |
| Redhill Biopharma Inc. | 2 | $37 |
| Medtronic | 2 | $37 |
| Dexcom, Inc. | 2 | $36 |
| Merck | 2 | $30 |
| Eisai Inc. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
How this compares
$3,321 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $119,891 |
| MounjaroTirzepatide | 107 | $114,356 |
| EliquisApixaban | 59 | $51,087 |
| JanuviaSitagliptin Phosphate | 34 | $28,329 |
| XareltoRivaroxaban | 14 | $11,386 |
| MyrbetriqMirabegron | 11 | $9,319 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,781 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 29 | $6,459 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,242 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $6,171 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $6,094 |
| VascepaIcosapent Ethyl | 13 | $5,965 |
| Rosuvastatin Calcium | 391 | $3,463 |
| SynthroidLevothyroxine Sodium | 59 | $3,228 |
| Levemir FlexpenInsulin Detemir | 11 | $3,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $441 | $119,891108 claims |
| Lilly USA, LLCMounjaro | $429 | $114,356107 claims |
| PfizerEliquis | $42 | $51,08759 claims |
| MerckJanuvia | $30 | $28,32934 claims |
| GSKBreo Ellipta, Shingrix | $305 | $14,23943 claims |
| Boehringer IngelheimCombivent Respimat, Stiolto Respimat | $145 | $12,41324 claims |
| Astellas Pharma US IncMyrbetriq | $123 | $9,31911 claims |
| AbbVieSynthroid | $243 | $3,22859 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in New Bern
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.